The Government of Ceará has offered a benefit package for Prati-Donaduzzi
The Government of Ceará has offered a benefit package for Prati-Donaduzzi - Brazil's largest generic drug producer * - to build its new manufacturing facility in the state. Among the advantages presented by the government of Ceará to the pharmaceutical industry based in Toledo, in western Paraná, is tax exemptions.
The request to house an industry branch in Ceará was made by the Governor, Camilo Santana, on Wednesday (7), during a visit to the factory in Toledo.
According to Santana, Ceará has a favorable environment in the economic, logistic, educational and health sectors to receive a facility from the Pharmaceutical Industry. Moreover, the state wants its health area to be a model for the country. “We believe Prati-Donaduzzi can help improve our socioeconomic indicators”, said the Governor.
The interest of bringing industry to the northeast also aims to achieve the goals of the State Development Plan - “Ceará 2050” - that aims to generate new jobs and increase the average salary of Ceará.
“We want to have companies in our state that invest in research and development. Prati-Donaduzzi is a reference. “We want you as partners”, said Santana.
According to Prati-Donaduzzi CEO Eder Fernando Maffissoni, the benefits package offered by the Governor is very attractive. "We need, in an emergency, to build a new manufacturing facility", he said.
According to Prati-Donaduzzi CEO Eder Fernando Maffissoni, the benefits package offered by the Governor is very attractive
Withdrawals and the company's decision to build the new plant in Toledo or elsewhere will be announced within the next 30 days. In July, the CEO of the Pernambuco Economic Development Agency (AD Diper), Roberto de Abreu, was also at Prati-Donaduzzi offering tax advantages to house the plant in that state.
"Even if we decide to stay in Toledo, we don't rule out opening a Distribution Center in the Northeast", Maffissoni announced.
According to Maffissoni, the construction of a new facility is one of the company's priorities, as it already has several medicines approved by the National Health Surveillance Agency (Anvisa) to be produced and marketed. However, Toledo´s facility has reached its maximum production capacity. "Although we have already purchased new equipment and are expanding one of the plants, we need a new facility", he said.
The new facility will be built in compliance with international legislation and will have the capacity to produce 3.6 billion doses of generic drugs per year.
Eder Fernando Maffissoni and the directors Marcelo Sáfadi Alvares (Finance), André Pozza (Supplies and Logistics) and Laura Castanheira (Institutional) welcomed the governor’s entourage, formed by the Secretaries Francisco Maia Junior (Economic Development); Carlos Roberto Martins - Cabeto (Health) and Chagas Vieira (Communication).
*IQVIA MAT JUN/2019 PMB + NRC Doses Terapêuticas